Published in AIDS Weekly, August 30th, 1999
HU, an anticancer agent of long standing, inhibits the cellular enzyme ribonucleotide reductase and leads to reduced pools of deoxynucleotide triphosphates (dNTPs). Reduced pools of dNTPs favor HIV uptake of nucleoside analog inhibitors of HIV reverse transcriptase.
As the most pronounced reduction of dNTP is among deoxyadenosine triphosphates (dATPs), Stanford researchers Sarah Palmer and colleagues explored the synergy between HU and three adenosine-based nucleoside-analog reverse transcriptase inhibitors...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.